Valens GroWorks Corp. (CSE:VGW) (the “Company” or “Valens”), is pleased to announce the signing of a Memorandum of Understanding (“MOU“) with the Bill Nelems Pain and Research Centre, operating the Okanagan Interventional Pain Clinic, to form a strategic alliance for the purpose of conducting clinical research and development of safe, efficacious and reliable pharmaceutical-grade medicinal cannabis products (CBD and THC combinations) specific for the treatment of particular conditions.

The Bill Nelems Pain and Research Centre (“BNPRC“) serves as the main referral pain centre for approximately 750,000 patients within the Interior Health region, as well as patients from the Northern Health region in British Columbia. This centre specializes in comprehensive pain care, including cutting-edge interventional options, and interdisciplinary pain management.
Tyler Robson, CEO of Valens stated, “It is a great honour to forge this alliance with BNPRC, and an opportunity to realize our vision as a high-science company at the forefront of the cannabis sector, and our objective towards becoming a leading purveyor of cannabis products and technologies.” Robson adds, “The collaboration of our scientists with front-line physicians fast-tracks the development of effective and reliable pharmaceutical-grade medicinal cannabis products to best serve prescribing physicians and their patients. The resulting formulations will platform an industry-leading Valens RX™ line of products with proven efficacy that doctors, and their patients, can rely on.”
Dr. Paul Etheridge, the Medical Director at the BNPRC commented, “Our doctors have been prescribing medicinal marijuana as an alternative to pharmaceutical drugs such as opioids for the treatment of various conditions, including the reduction of chronic pain and PTSD.” He continued, “It is however challenging to determine the effective combination of CBD and THC and other cannabinoids for treatment of patients and particular conditions. This collaboration provides us access to Valens’ high-level analytical testing capabilities and licensed capability to develop customized medicinal formulations from Cannabis plants.”
Dr, Rob O’Brien, President of Valens AgriTech Ltd and Chief Scientific Officer at Supra THC Services, Valens’ Health Canada licenced wholly-owned subsidiaries, added, “In order for Cannabis based products to be acceptable as medicines, physicians need to understand the complex relationship between a prescribed dose and how the Cannabis cannabinoids interact with the patient’s system. Our Center of Excellence in “Plant Based Medicine Analytics” possesses the advanced instrumentation and scientific expertise needed to measure cannabinoid metabolites as well as the patient’s biomarkers. This strategic alliance with front-line physicians will lead to an increased understanding of how Cannabis products interact with the human system and may provide physicians with a natural and effective alternative to opioids and other potentially harmful pharmaceuticals when treating chronic pain and related conditions.”
About Valens GroWorks Corp.
Valens GroWorks Corp. is a CSE-listed biotechnology company with an aggressive buildout strategy. The Company seeks to capture a broad spectrum of medical cannabis users, and adult recreational users once legalized, as well as clinical trial and R&D clients, in pursuit of its ambitious “plants to premium products” objectives. The Company also provides management, consulting, testing and support services to domestic and international clients.
The Company operates a 17,000 square foot facility located on two acres in Kelowna, in the heart of British Columbia’s Okanagan Valley. Wholly owned subsidiary Supra THC Services Inc. (“Supra“) recently announced a collaboration with Thermo Fisher Scientific, a world leader in Health Science services, to develop a “Centre of Excellence in Plant Based Medicine Analytics” to provide analytical services and directed research and development, including clinical trials. Supra, and the Company’s wholly owned subsidiary Valens AgriTech Ltd. (“Valens AgriTech“), a Health Canada Licensed Dealer, recently announced a $330,000 MITACS funded research grant to support a collaboration with UBC Okanagan and Thompson Rivers University to explore potential cannabis bio-products including pharmaceuticals, nutritional products, and industrial fiber.
On behalf of the Board of Directors,
VALENS GROWORKS CORP.
(signed) “Tyler Robson
Chief Executive Officer
Notice regarding Forward Looking Statements
This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.
Click here to connect with Valens GroWorks Corp. (CSE:VGW) for an Investor Presentation


Source: www.newswire.ca

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) (“Curaleaf” or the “Company”), a leading international provider of consumer products in cannabis, today announced Boris Jordan Curaleaf Executive Chairman, will participate in Cantor Fitzgerald’s cannabis focused “Weednesday Series” investor fireside chat on June 30, 2021 at 11:00 am ET .

The event will be hosted by Pablo Zuanic , Managing Director, U.S. Consumer and Cannabis Equity Analyst at Cantor Fitzgerald and will be webcast live. To access the fireside chat webcast, please visit the investor relations section of the Curaleaf website, under the events tab, at https://ir.curaleaf.com/events .

Keep reading... Show less

Code Investment Love Hemp Announces Major Deal that Will See Anthony Joshua as Brand Ambassador and Collaborator on Licensed Range of CBD Products for Athletes

Codebase Ventures Inc. (“Codebase” or the “Company”) (CSE:CODE)(FSE:C5B)(OTCQB:BKLLF) is excited to announce that the Company’s investment, Love Hemp Group Plc. has signed a major endorsement agreement with World Heavyweight Champion, Anthony Joshua, (https:twitter.comanthonyjoshua

Keep reading... Show less

Canbud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“Canbud” or the “Corporation”) is pleased to announce that its subsidiary Empathy Plant Co. has joined Plant-Based Foods of Canada (PBFC).

PBFC was founded in 2018 and has since acted as the collective voice of plant-based food companies. As a division of Food, Health & Consumer Products of Canada (FHCP), they work to keep consumers, governments and industry participants informed about the benefits of plant-based foods. The goal of PBFC is to move regulations forward to support innovation, growth and make plant-based eating more available to the masses.

Keep reading... Show less

 Trulieve Cannabis Corp. (” Trulieve ” or the ” Company “) (CSE: TRUL) (OTC: TCNNF) and Harvest Health & Recreation Inc. (” Harvest “) (CSE: HARV) (OTCQX: HRVSF) today  announced the expiration of the 30-day waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (the “HSR Act”) in connection with the previously announced proposed acquisition (the “Transaction”).

Trulieve CEO Kim Rivers commented, “Completion of the HSR milestone is exciting and we will continue to work toward closing this strategic transaction. Upon closing, we expect to leverage the expertise and resources of the combined companies to realize meaningful scale and expansion for years to come.”

Keep reading... Show less

Little Green Pharma Ltd (ASX: LGP) has acquired a world-class, fully-operational, GMP medicinal cannabis cultivation and manufacturing facility in Denmark from Canopy Growth Corporation (TSX:WEED, NASDAQ: CGC).

The facility, located in Northern Odense , has the capacity to produce in excess of 12 tonnes per annum of finished flower and provides LGP with much-needed product supply from its current inventory of ~1 tonne of medicinal cannabis flower products.

Keep reading... Show less